Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Obesity · 2025-11 · 33 (11) · 2046-2054
DOI: 10.1002/oby.24360 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Obesity, online erschienen am 20.07.2025. Verfasst von Binayak Sinha und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Manipal Hospital, Kolkata, India. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare the efficacy and safety of GLP‐1 receptor agonists (GLP‐1RAs), dual agonists (GLP‐1RAs/GIP or GCGR), and retatrutide (GLP‐1/GIP/glucagon) for weight loss in adults with overweight or obesity.
Methods
We conducted a systematic review and Bayesian network meta‐analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m 2 ), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo. Outcomes included mean weight loss, achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight loss, waist circumference (WC), BMI, and adverse events (AEs) at ≥ 36 weeks. Subgroup and meta‐regression analyses evaluated the impact of diabetes status, sex, age, and BMI.
Results
Retatrutide and dual agonists achieved equivalent mean weight loss (−11.0 kg), surpassing GLP‐1RAs (−9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP‐1RAs followed (OR 16.4 and 9.0, respectively). Retatrutide had the highest AE risk. Meta‐regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP‐1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female‐dominant or high‐BMI cohorts.
Conclusions
Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy–safety balance. Personalized treatment selection based on patient characteristics is recommended. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Manipal Hospital, Kolkata, India.
- Department of Internal Medicine, Nightingale Hospital, Kolkata, India.
ORCID-Profile: Samit Ghosal
Zitieren
APA
Sinha, B., & Ghosal, S. (2025). Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity, 33(11), 2046-2054. https://doi.org/10.1002/oby.24360
Vancouver
Sinha B, Ghosal S. Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity. 2025;33(11):2046-2054. doi:10.1002/oby.24360
BibTeX
@article{Sinha2025,
author = {Sinha, Binayak and Ghosal, Samit},
title = {Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA},
journal = {Obesity},
year = {2025},
volume = {33},
number = {11},
pages = {2046--2054},
doi = {10.1002/oby.24360}
}
EUVIMED